Barclays raised the firm’s price target on Danaher to $270 from $260 and keeps an Equal Weight rating on the shares post the Q1 report. The company’s orders came in above expectations, the analyst tells investors in a research note. The firm says bioprocessing names continue to be favored by investors and that it does not see this changing in the near term.